Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 12 862 / https://doi.org/10.3332/ecancer.2018.862

Case Report

Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas

Neurofibromatosis 1 (NF1) is an autosomal dominant tumour predisposition disorder with a birth incidence of about 1 in 2,700 and prevalence of 1 in 4,560. The NF1 gene codes for an ubiquitous protein: neurofibromin. Neurofibromin interacts with the proto-oncogene RAS to suppress tumour formation. Individuals with germline inactivation of the NF1 gene have a propensity to develop both benign and malignant tumours.

We report the case of a 12-year-old child with NF1, diagnosed at the age of 15 months, for whom the clinical course has been marked by the appearance of multiple cutaneous and paraspinal neurofibromas responsible for impaired walking, motor deficiency and pain. A treatment with an MEK inhibitor, trametinib, was initiated and led to a quick and sustained clinical response.

Keywords: MEK, children, neurofibromatosis, neurofibroma, glioma

Loading Article Metrics ... Please wait

Related articles

Review: Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update

Abstract | Full Article | PDF Published: 11 Mar 2019 / https://doi.org/10.3332/ecancer.2019.909

Case Report: Laser thermal ablation to treat a recurrent soft-tissue sarcoma of the leg: a case report

Abstract | Full Article | PDF Published: 05 Mar 2019 / https://doi.org/10.3332/ecancer.2019.908

Review: Petroclival meningiomas: radiological features essential for surgeons

Abstract | Full Article | PDF Published: 05 Mar 2019 / https://doi.org/10.3332/ecancer.2019.907

Research: Younger age and previous exposure to radiation therapy are correlated with the severity of chemotherapy-induced thrombocytopenia

Abstract | Full Article | PDF Published: 26 Feb 2019 / https://doi.org/10.3332/ecancer.2019.906

Review: The use of intravesical BCG in urothelial carcinoma of the bladder

Abstract | Full Article | PDF Published: 26 Feb 2019 / https://doi.org/10.3332/ecancer.2019.905



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation